ArticleESMO open2026

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.

C Blaye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.